Medical technology company Conformis is set to be acquired by restor3d, as recommended by independent proxy advisory firm Institutional Shareholder Services Inc. (ISS). The pending merger, wherein restor3d will purchase all outstanding Conformis shares for $2.27 per share in cash, has received unanimous approval from the Conformis Board of Directors. A virtual special meeting is scheduled for August 31, 2023, for stockholders to vote on the proposed merger, with the company urging prompt proxy submission. The merger aims to benefit all Conformis stockholders, as affirmed by ISS.
Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. (“ISS”), has recommended that Conformis stockholders vote “FOR” the pending merger transaction with restor3d.
As previously announced, under the terms of the definitive merger agreement, restor3d will acquire all outstanding shares of common stock of Conformis for $2.27 per share in an all cash transaction. Conformis is pleased that ISS shares its belief that the proposed merger with restor3d is in the best interests of all Conformis stockholders.
Special Meeting
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
The Conformis Board of Directors has unanimously recommended that stockholders vote “FOR” the proposal to approve the pending merger with restor3d in advance of the special meeting, which will be held virtually on August 31, 2023 at 12:00 PM, Eastern Time.
The Company encourages stockholders to submit their proxy as soon as possible, whether over the Internet, by telephone or by mail. To be valid, your vote must be received by 11:59 p.m. (Eastern Time) on August 30, 2023, the day preceding the special meeting of stockholders.
Further details on how to vote and the requirements with respect to attending the meeting virtually are contained in the definitive proxy statement on Schedule 14A filed with the Securities Exchange Commission (the “SEC”) and mailed to stockholders of record on July 14, 2023.
Source: BioSpace